Home › NDC Lookup › Ingredients › Acetaminophen › 45802-0730-30
acetaminophen pain reliever fever reducer 650 mg Suppository, 12 suppositories — NDC 45802-0730-30 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

acetaminophen pain reliever fever reducer 650 mg Suppository, 12 suppositories — NDC 45802-730-30 (Billing 45802-0730-30)

by Padagis Israel Pharmaceuticals Ltd · 12 BLISTER PACK in 1 CARTON / 1 SUPPOSITORY in 1 BLISTER PACK

This is a package of 12 suppositories of acetaminophen pain reliever fever reducer 650 mg Suppository from Padagis Israel Pharmaceuticals Ltd, marketed since Oct 2010 and currently FDA-listed, this package's marketing is listed to end Nov 2026; retail pharmacies pay about $0.3494 per suppositorie (NADAC). It is the main listing for this product, which comes in 4 package sizes.

NDC 45802-0730-30
🏷️ FDA NDC (as labeled) 45802-730-30 billing pads the product segment with a zero
This package
Contains12 suppositories Cost per ea$0.3494 NADAC Per package$4.19 / 12 suppository Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.7081/unit — full pricing hub ↓
Main listing for product 45802-730 · Also comes in: 1 suppository 45802-730-00 50 suppositories 45802-730-32 100 suppositories 45802-730-33
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Acetaminophen (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Oct 21, 2025 — Defective Container (Kenvue Brands LLC) · FDA recall D-0121-2026
Class II · Aug 20, 2025 — Discoloration (Baxter Healthcare Corporation) · FDA recall D-0596-2025
Class II · May 22, 2025 — cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets). (Aurobindo Pharma USA Inc) · FDA recall D-0471-2025
Class I · Jul 8, 2024 — Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL) (Hikma Pharmaceuticals USA Inc.) · FDA recall D-0635-2024
Class II · May 20, 2024 — Discoloration: Brownish tablets (Contract Pharmacal Corporation) · FDA recall D-0566-2024
Class II · Nov 13, 2023 — Failed Impurities/Degradation Specifications (KINDER FARMS LLC) · FDA recall D-0143-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-730-30
Product NDC 45802-730
11-digit billing NDC 45802073030
NCPDP billing unit EA — each (per item)
RxCUI 198443
UNII 362O9ITL9D
Application # ANDA070608
SPL Set ID b43974c3-4db9-4201-beee-b22596a2b241
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2010-10-28
Marketing end 2026-11-30
Route RECTAL
Dosage form SUPPOSITORY
Substance ACETAMINOPHEN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 64200010005220
GPI class Acetaminophen
GCN Seq No 004478
GCN 16907
HICL code 001866
Ingredient (HICL) Acetaminophen
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H3
Therapeutic class — intermediate (HIC2) Analgesics
HIC3 code H3E
Therapeutic class — specific (HIC3) Analgesic/Antipyretics,Non-Salicylate
AHFS code 28:08.16.00
AHFS class Non-Opioid Analgesics
FDB label name ACETAMINOPHEN 650 MG SUPPOS
FDB brand name Acetaminophen
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 004478
  • GCN: 16907
  • GPI-14 (Medi-Span): 64200010005220
  • HICL (First Databank): 001866
  • AHFS class code: 28:08.16.00
  • RxCUI (RxNorm): 198443
Why two NDCs? The FDA registers this code as 45802-730-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0730-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Anilides class.

Drug family (ATC) Anilides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ACETAMINOPHEN 650 MG SUPPOS Ingredient Acetaminophen
📖 What it is MedlinePlus · NLM

Acetaminophen rectal is used to relieve mild to moderate pain and to reduce a fever. Acetaminophen is in a class of medications called analgesics (pain relievers) and antipyretics (fever reducers). It works by changing the way the body senses pain and by cooling the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It temporarily relieves minor aches and pains, like headache, backache, toothache, muscle aches, cold aches, minor arthritis pain and menstrual cramps. It also reduces fever.
  • Follow your product label or prescriber exactly and never exceed the maximum daily amount. Remember that the limit counts every product with acetaminophen. Too much can seriously d...
  • Check the label first. Many combination products also contain acetaminophen, and you shouldn't use two together. If you aren't sure, ask me or your pharmacist.
  • Having 3 or more alcoholic drinks every day while using it raises the risk of liver damage. If you take warfarin, talk with your doctor or pharmacist first, since regular high dail...
📖 Read our full Acetaminophen guide →
1
Nutrient depletion considerations

Acetaminophen may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.349 $4.19 / 12 suppository
Medicaid paysCMS SDUD · 12 mo $0.7081 $8.50 / 12 suppository
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Jan 2026 Sep 2026 $0.354 $0.325
▲ Up 6% over the last 23 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0730-00 45802-730-00 1 SUPPOSITORY in 1 BLISTER PACK $0.3494 / ea $0.35 2010-10-28 Nov 30, 2026 Active
45802-0730-30 You're viewing this Main listing 12 BLISTER PACK in 1 CARTON / 1 SUPPOSITORY in 1 BLISTER PACK $0.3494 / ea $4.19 2010-10-28 Nov 30, 2026 Active
45802-0730-32 45802-730-32 50 BLISTER PACK in 1 CARTON / 1 SUPPOSITORY in 1 BLISTER PACK $0.3466 / ea $17.33 2010-11-22 Nov 30, 2026 Active
45802-0730-33 45802-730-33 100 BLISTER PACK in 1 CARTON / 1 SUPPOSITORY in 1 BLISTER PACK $0.3494 / ea $34.94 2010-10-28 Nov 30, 2026 Active

In Medicaid, this is the most-dispensed pack of this product — about 93% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 12 suppositories — 12 blister pack in 1 carton / 1 suppository in 1 blister pack.
How does this package differ from NDC 45802-0730-00?
Both are acetaminophen pain reliever fever reducer 650 mg Suppository — the drug itself is identical. This page's package is the 12 suppositories one, while NDC 45802-0730-00 is the 1 suppository package.
What NDC number is used to bill for this package of acetaminophen pain reliever fever reducer 650 mg Suppository?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
acetaminophen pain reliever fever reducer 650 mgthis 45802-0730-30 Padagis 12 suppositories $0.349 — Availability likely —
foster and thrive pain reliever 650 mg 70677-1271-01 Strategic 12 suppositories $0.349 — Availability likely —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2010
On the market since
Oct 2010
📍
2026
Currently FDA-listed
16 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII H3E878020N
    Cottonseed oil is a natural vegetable oil extracted from cotton plant seeds. It is used in medicines as a solvent and lubricant to help dissolve active ingredients and allow smooth tablet or capsule movement through manufacturing equipment.

1 inactive ingredient listed in the exact product block matched to this NDC.

The official label also stateshydrogenated vegetable oil

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPERRIGO NEW YORK INC
FDA applicationANDA070608 (ANDA)
Labeler code45802
First marketedOct 2010
Product typeHuman Otc Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 12 words ▾

Uses temporarily • reduces fever • relieves minor aches, pains, and headache

⏱️ Dosage and Administration 58 words ▾

Directions • do not use more than directed • remove wrapper • carefully insert suppository well up into the rectum • adults and children 12 years and older: • 1 suppository every 4 to 6 hours while symptoms last • do not exceed 6 suppositories in any 24 hour period • children under 12 years: ask a doctor

⚠️ Warnings ~1 min read ▾

Warnings Liver warning: This product contains acetaminophen. Severe liver damage may occur if • an adult or child 12 years and older takes more than 6 doses in 24 hours, which is the maximum daily amount • taken with other drugs containing acetaminophen • an adult takes 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions. Symptoms may include: • skin reddening • blisters • rash If a skin reaction occurs, stop use and seek medical help right away.

For rectal use only Do not use • in children under 12 years • if you are allergic to acetaminophen • with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. Ask a doctor before use if • you have liver disease • you are taking the blood thinning drug warfarin Stop use and ask a doctor if • fever lasts more than 3 days (72 hours), or recurs. • pain gets worse or lasts more than 10 days. • new symptoms occur. • redness or swelling is present in the painful area.

These may be signs of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.

If swallowed or in case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222) Quick medical attention is critical in case of overdose for adults and for children even if you do not notice any signs or symptoms.

📦 Storage and Handling 32 words ▾

Other information • store at 20-25 ° C (68-77 ° F) or in a cool place • tamper-evident: suppositories are individually wrapped. Do not use if printed wrapper is opened or damaged.

🧪 Active Ingredient 9 words ▾

Active ingredient (in each rectal suppository) Acetaminophen 650 mg

🧪 Inactive Ingredients 5 words ▾

Inactive ingredient hydrogenated vegetable oil

🎯 Purpose 4 words ▾

Purposes Pain reliever/fever reducer

📄 Do Not Use 41 words ▾

Do not use • in children under 12 years • if you are allergic to acetaminophen • with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist.

📄 Ask a Doctor Before Use If 20 words ▾

Ask a doctor before use if • you have liver disease • you are taking the blood thinning drug warfarin

📄 Stop Use and Ask a Doctor If 50 words ▾

Stop use and ask a doctor if • fever lasts more than 3 days (72 hours), or recurs. • pain gets worse or lasts more than 10 days. • new symptoms occur. • redness or swelling is present in the painful area. These may be signs of a serious condition.

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 49 words ▾

Keep out of reach of children. If swallowed or in case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222) Quick medical attention is critical in case of overdose for adults and for children even if you do not notice any signs or symptoms.

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-719-9260

📄 Package Label / Principal Display Panel 33 words ▾

Principal Display Panel Compare to FeverAll ® active ingredient For Adults Acetaminophen Suppositories USP, 650 mg Pain Reliever/Fever Reducer Ages 12 years and older 12 RECTAL SUPPOSITORIES, 650 mg EACH Padagis ® padagis-acetaminophen-suppositories-carton-image.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
6.3K
Units reimbursed last 4 qtrs
105.8K
Gross reimbursed last 4 qtrs
$74.9K
Avg / prescription
$11.94
Avg / unit
$0.7081
Latest quarter Q1 2026
1.8KRx
Medicaid pays / ea
$0.7081
gross reimbursed
vs
NADAC / ea
$0.3494
acquisition cost
=
Spread
+$0.3587
+103% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
54% FFS 46% MCO
Fee-for-service · 3,412 Rx Managed care · 2,861 Rx
State Medicaid map
Alaska: no data reported AK Maine: 1,152 units · 82.6 per 100k residents ME Washington: 3,206 units · 41.0 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 4,883 units · 85.1 per 100k residents MN Wisconsin: 3,631 units · 61.4 per 100k residents WI Michigan: 3,511 units · 35.0 per 100k residents MI New York: 19,695 units · 101 per 100k residents NY Vermont: 418 units · 64.6 per 100k residents VT New Hampshire: 524 units · 37.4 per 100k residents NH Oregon: 1,838 units · 43.4 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 14,140 units · 206 per 100k residents IN Ohio: 4,373 units · 37.1 per 100k residents OH Pennsylvania: 6,798 units · 52.4 per 100k residents PA New Jersey: 1,545 units · 16.6 per 100k residents NJ Massachusetts: 3,454 units · 49.3 per 100k residents MA California: 22,984 units · 59.0 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 1,224 units · 61.9 per 100k residents NE Missouri: no data reported MO Kentucky: 3,719 units · 82.2 per 100k residents KY West Virginia: no data reported WV Virginia: 4,213 units · 48.3 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 398 units · 5.4 per 100k residents AZ New Mexico: no data reported NM Kansas: 248 units · 8.4 per 100k residents KS Arkansas: no data reported AR Tennessee: 184 units · 2.6 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: 141 units · 20.8 per 100k residents DC Hawaii: 705 units · 49.1 per 100k residents HI Texas: 2,804 units · 9.2 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
2.6206
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Indiana 206 /100k
2 New York 101 /100k
3 Minnesota 85.1 /100k
4 Maine 82.6 /100k
5 Kentucky 82.2 /100k
6 Vermont 64.6 /100k
7 Nebraska 61.9 /100k
8 Wisconsin 61.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 6,712 Rx · 111,975 units · $80,390 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Acetaminophen (matched by generic name) — the program that covers self-administered drugs. 5 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Acetaminophen. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$34K
Claims incl. refills
277
Beneficiaries
145
Spend / beneficiary
$234.25
Spend / claim
$122.62
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for acetaminophen pain reliever fever reducer (this brand).

Top reported reactions

Fatigue20,900
Pain18,465
Nausea18,163
Headache17,128
Toxicity To Various Agents15,843
Dyspnoea15,012
Pyrexia14,572

Age at onset

Neonate562
Infant376
Child2,615
Adolescent2,132
Adult26,646
Elderly17,765

Reporter sex

253,607 reports
Male · 38%
Female · 62%
Unknown · 0%

Serious outcomes

Hospitalization114,299
Death49,981
Life-threatening21,904
Disabling12,022
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 28,614 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.